×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CYTK – cytokinetics, incorporated (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CYTK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
08:27 am
cytk
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Mizuho from $99.00 to $103.00. They now have an "outperform" rating on the stock.
Medium
Report
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Mizuho from $99.00 to $103.00. They now have an "outperform" rating on the stock.
11/20
11:12 am
cytk
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan [Yahoo! Finance]
Low
Report
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan [Yahoo! Finance]
11/20
08:07 am
cytk
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
Medium
Report
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
11/19
08:45 am
cytk
Cytokinetics and Bayer partner to develop for aficamten in Japan [Seeking Alpha]
Low
Report
Cytokinetics and Bayer partner to develop for aficamten in Japan [Seeking Alpha]
11/19
05:39 am
cytk
Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan [Yahoo! Finance]
Medium
Report
Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan [Yahoo! Finance]
11/19
03:30 am
cytk
Bayer acquires rights to Cytokinetics' heart drug in Japan [Yahoo! Finance]
Low
Report
Bayer acquires rights to Cytokinetics' heart drug in Japan [Yahoo! Finance]
11/19
02:30 am
cytk
Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan
Low
Report
Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan
11/18
08:07 am
cytk
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Medium
Report
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2024
04:00 pm
cytk
cytokinetics, incorporated
MISS
Report
0.6%
cytokinetics, incorporated
8/8/2024
04:00 pm
cytk
cytokinetics, incorporated
MISS
Report
3.3%
cytokinetics, incorporated
5/8/2024
04:00 pm
cytk
cytokinetics, incorporated
MISS
Report
-1.9%
cytokinetics, incorporated
2/27/2024
04:00 pm
cytk
cytokinetics, incorporated
MISS
Report
-9.8%
cytokinetics, incorporated
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/19
04:16 pm
cytk
Form 4 CYTOKINETICS INC For: Nov 18 Filed by: Blum Robert I
Low
Report
Form 4 CYTOKINETICS INC For: Nov 18 Filed by: Blum Robert I
11/19
06:03 am
cytk
Form 8-K CYTOKINETICS INC For: Nov 18
Medium
Report
Form 8-K CYTOKINETICS INC For: Nov 18
11/18
04:32 pm
cytk
Form 144 CYTOKINETICS INC Filed by: Blum Robert I
Low
Report
Form 144 CYTOKINETICS INC Filed by: Blum Robert I
11/14
01:29 pm
cytk
Form SC 13G CYTOKINETICS INC Filed by: T. Rowe Price Investment Management, Inc.
Low
Report
Form SC 13G CYTOKINETICS INC Filed by: T. Rowe Price Investment Management, Inc.
11/13
05:04 pm
cytk
Form 4 CYTOKINETICS INC For: Nov 12 Filed by: Malik Fady Ibraham
Low
Report
Form 4 CYTOKINETICS INC For: Nov 12 Filed by: Malik Fady Ibraham
11/12
04:09 pm
cytk
Form 144 CYTOKINETICS INC Filed by: Malik Fady Ibraham
Low
Report
Form 144 CYTOKINETICS INC Filed by: Malik Fady Ibraham
11/12
02:22 pm
cytk
Form SC 13G/A CYTOKINETICS INC Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A CYTOKINETICS INC Filed by: VANGUARD GROUP INC
11/12
11:44 am
cytk
Form SC 13G/A CYTOKINETICS INC Filed by: BlackRock, Inc.
Low
Report
Form SC 13G/A CYTOKINETICS INC Filed by: BlackRock, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/12
Form 4 CYTOKINETICS INC For: Dec 10 Filed by: BVF INC/IL
12.1%
5/9 Form 8-K CYTOKINETICS INC For: May 09 11.8%
2/14 Form SC 13G/A CYTOKINETICS INC Filed by: Point72 Asset Management, L.P. 10.3%
11/18 Form 4 CYTOKINETICS INC For: Nov 15 Filed by: Blum Robert I 10.3%
5/6 Cytokinetics plunges 19% after Phase 2 trial of ALS drug fails to meet endpoints [MarketWatch] 9.6%
4/8 Cytokinetics to Participate in the 19th Annual Needham Virtual Healthcare Conference 8.9%
3/30 Form DEFA14A CYTOKINETICS INC 8.9%
1/13 Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones 8.0%
4/1 Form SC 13G/A CYTOKINETICS INC Filed by: BIOTECHNOLOGY VALUE FUND L P 6.3%
8/16 Cytokinetics, Inc. (NASDAQ: CYTK) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 6.2%
5/9 Form 8-K CYTOKINETICS INC For: May 09 11.8%
2/14 Form SC 13G/A CYTOKINETICS INC Filed by: Point72 Asset Management, L.P. 10.3%
11/18 Form 4 CYTOKINETICS INC For: Nov 15 Filed by: Blum Robert I 10.3%
5/6 Cytokinetics plunges 19% after Phase 2 trial of ALS drug fails to meet endpoints [MarketWatch] 9.6%
4/8 Cytokinetics to Participate in the 19th Annual Needham Virtual Healthcare Conference 8.9%
3/30 Form DEFA14A CYTOKINETICS INC 8.9%
1/13 Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones 8.0%
4/1 Form SC 13G/A CYTOKINETICS INC Filed by: BIOTECHNOLOGY VALUE FUND L P 6.3%
8/16 Cytokinetics, Inc. (NASDAQ: CYTK) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 6.2%
TOP News Decliners
11/6
Edited Transcript of CYTK earnings conference call or presentation 31-Oct-19 8:30pm GMT [Yahoo! Finance News]
-23.6%
11/8 Form 305B2 CYTOKINETICS INC -11.2%
3/6 Cytokinetics, Inc. (NASDAQ: CYTK) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -10.3%
9/6 Form 4 CYTOKINETICS INC For: Sep 05 Filed by: Malik Fady Ibraham -10.1%
5/22 Form 3 CYTOKINETICS INC For: May 15 Filed by: Wong Robert -9.5%
12/16 Cytokinetics: Big Insider Buying By Beneficial Owner [Seeking Alpha] -9.2%
4/29 Form 4 CYTOKINETICS INC For: Apr 28 Filed by: WIERENGA WENDALL -7.2%
4/1 Cytokinetics, Inc. (NASDAQ: CYTK) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -5.4%
1/23 Form SC 13G/A CYTOKINETICS INC Filed by: INTEGRATED CORE STRATEGIES (US) LLC -5.1%
12/18 Cytokinetics Granted Orphan Drug Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis -5.1%
11/8 Form 305B2 CYTOKINETICS INC -11.2%
3/6 Cytokinetics, Inc. (NASDAQ: CYTK) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -10.3%
9/6 Form 4 CYTOKINETICS INC For: Sep 05 Filed by: Malik Fady Ibraham -10.1%
5/22 Form 3 CYTOKINETICS INC For: May 15 Filed by: Wong Robert -9.5%
12/16 Cytokinetics: Big Insider Buying By Beneficial Owner [Seeking Alpha] -9.2%
4/29 Form 4 CYTOKINETICS INC For: Apr 28 Filed by: WIERENGA WENDALL -7.2%
4/1 Cytokinetics, Inc. (NASDAQ: CYTK) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -5.4%
1/23 Form SC 13G/A CYTOKINETICS INC Filed by: INTEGRATED CORE STRATEGIES (US) LLC -5.1%
12/18 Cytokinetics Granted Orphan Drug Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis -5.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: